{
  "trial_id": "NCT02056756",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Patient \u2265 18 years old.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Female patient is either post-menopausal or surgically sterilized or commits continued abstinence from heterosexual intercourse during the duration of the study or is willing to use two methods of birth control, one highly effective method and one additional effective method at the same time, at least 4 weeks before starting carfilzomib and bendamustine therapy, during carfilzomib and bendamustine therapy and for at least 4 weeks after stopping carfilzomib and bendamustine therapy.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Male patient agrees to use an acceptable method for contraception (i.e., condom or abstinence) for the duration of the study and for 6 months after stopping study therapy.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient with relapsed or/and refractory multiple myeloma after failure of two or more treatment regimens (previous bortezomib is allowed).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient has measurable disease, defined as follows: any quantifiable serum monoclonal protein (M-protein) value (generally, but not necessarily, \u2265 0.5 g/dL of M-protein) and, where applicable, urine light-chain excretion of >200 mg/24 hours.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient has a Karnofsky performance status \u226560%.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient has a life expectancy >6 months.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient has the following laboratory values within 14 days before Baseline (day 1 of the Cycle 1, before study drug administration): Platelet count \u226570 x 10^9/L (\u226550 x 10^9 /L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to drug administration).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Absolute neutrophil count (ANC) \u2265 1 x 10^9/L without the use of growth factors.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Corrected serum calcium \u226414 mg/dL (3.5 mmol/L).",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or lactating females",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Patient has active infectious hepatitis type B or C or HIV.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Patients with active congestive heart failure (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention.",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination.",
  "_meta": {
    "topic_id": "46",
    "trial_id": "NCT02056756",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}